Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment

CompletedOBSERVATIONAL
Enrollment

56

Participants

Timeline

Start Date

June 25, 2019

Primary Completion Date

January 31, 2021

Study Completion Date

January 31, 2021

Conditions
Von Willebrand Diseases
Interventions
DRUG

Von Willebrand Factor-Containing Product

Active substances: VWF concentrates, VWF/FVIII concentrates, Cryoprecipitate VWF-containing products licensed in each participating country

Trial Locations (15)

1134

Medical Centre Hungarian Defence Forces, Budapest

4032

Debreceni Egyetem Klinikai Központ, Regionális Haemophilia és Thrombophilia Központ, Debrecen

7624

University Clinical Center, Department of Internal Medicine, Hematology, Pécs

9010

"UMHAT Sveta Marina EAD.", Varna

10000

University Hospital Centre Zagreb, Zagreb

30329

Children's Healthcare of Atlanta, Atlanta

79035

"Community Institution of Lviv Oblast Council West-Ukrainian Specialized Children's Medical Center", Lviv

119049

Morosovskaya Children Clinical Hospital, Moscow Health Department, Department of General Hematology with the Pathology of Hemostasis, Moscow

610027

Federal State Budgetary Scientific Institution Kirov Scientific-Research Institute of Hematology and Blood Transfusion of Federal, Kirov

Unknown

Republican Research Center for Radiation Medicine and Human Ecology, Homyel

"Specialized Hospital for Active Treatment of Haematological Diseases EAD, Sofia", Sofia

American University of Beirut Medical Center, Beirut

Nini Hospital, Tripoli

BP166830

Hotel Dieu de France Hospital, Beirut

01135

"State Institution National Children's Specialized Hospital OKHMATDYT of the Ministry of Health of Ukraine, Center of Hemostasis Pathology", Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Octapharma

INDUSTRY